Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Sechi A, Dardis A, Bembi B. Ther Clin Risk Manag. 2016; 12:53–58.On page 57, left column, line 22, the text “patients who result in poor metabolizers should not be treated with this drug” should have been “patients who result in CYP2D6 ultra-rapid metabolizers...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-07-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | https://www.dovepress.com/corrigendum-profile-of-eliglustat-tartrate-in-the-management-ofnb-peer-reviewed-article-TCRM |